The increased levels of IL-8 as a negative biomarker of response to either anti-PD-1 and anti-CTLA-4 was confirmed in another independent study carried out on metastatic melanoma (n=29) and NSCLC (n=19) patients (41). The gene discussed is PDCD1; the disease is metastatic melanoma.